Design, power, and interpretation of studies in the standard murine model of ALS
- 1 January 2008
- journal article
- research article
- Published by Informa UK Limited in Amyotrophic Lateral Sclerosis
- Vol. 9 (1), 4-15
- https://doi.org/10.1080/17482960701856300
Abstract
Identification of SOD1 as the mutated protein in a significant subset of familial amyotrophic lateral sclerosis (FALS) cases has led to the generation of transgenic rodent models of autosomal dominant SOD1 FALS. Mice carrying 23 copies of the human SOD1(G93A) transgene are considered the standard model for FALS and ALS therapeutic studies. To date, there have been at least 50 publications describing therapeutic agents that extend the lifespan of this mouse. However, no therapeutic agent besides riluzole has shown corresponding clinical efficacy. We used computer modeling and statistical analysis of 5429 SOD1(G93A) mice from our efficacy studies to quantify the impact of several critical confounding biological variables that must be appreciated and should be controlled for when designing and interpreting efficacy studies. Having identified the most critical of these biological variables, we subsequently instituted parameters for optimal study design in the SOD1(G93A) mouse model. We retested several compounds reported in major animal studies (minocycline, creatine, celecoxib, sodium phenylbutyrate, ceftriaxone, WHI-P131, thalidomide, and riluzole) using this optimal study design and found no survival benefit in the SOD1(G93A) mouse for any compounds (including riluzole) administered by their previously reported routes and doses. The presence of these uncontrolled confounding variables in the screening system, and the failure of these several drugs to demonstrate efficacy in adequately designed and powered repeat studies, leads us to conclude that the majority of published effects are most likely measurements of noise in the distribution of survival means as opposed to actual drug effect. We recommend a minimum study design for this mouse model to best address and manage this inherent noise and to facilitate more significant and reproducible results among all laboratories employing the SOD1(G93A) mouse.Keywords
This publication has 35 references indexed in Scilit:
- Amyotrophic lateral sclerosis: recent advances and future therapiesCurrent Opinion in Neurology, 2005
- Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALSMolecular Brain Research, 2004
- Preclinical studies: how much can we rely on?Amyotrophic Lateral Sclerosis, 2004
- Genistein Is Neuroprotective in Murine Models of Familial Amyotrophic Lateral Sclerosis and StrokeBiochemical and Biophysical Research Communications, 1999
- The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studiesJournal of the Neurological Sciences, 1997
- A low expressor line of transgenic mice carrying a mutant human Cu,Zn superoxide dismutase ( SOD1 ) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosisActa Neuropathologica, 1997
- Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions.Proceedings of the National Academy of Sciences, 1996
- Age-Dependent Penetrance of Disease in a Transgenic Mouse Model of Familial Amyotrophic Lateral SclerosisMolecular and Cellular Neuroscience, 1995
- Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase MutationScience, 1994
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993